<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1437">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374526</url>
  </required_header>
  <id_info>
    <org_study_id>3205</org_study_id>
    <nct_id>NCT04374526</nct_id>
  </id_info>
  <brief_title>Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.</brief_title>
  <acronym>LIFESAVER</acronym>
  <official_title>Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Older age is an independent poor outcome predictor among COVID-19 hospitalized patients .
      Among 72,314 COVID-19 cases, case fatality rate (CFR) was 2.3% in total population, 8% in
      people aged 70 to 79, and 14.8% in those aged 80 and older. In the whole population, CFR was
      higher in people with comorbidities, ranging from 5-6% in persons with hypertension, chronic
      respiratory disease, diabetes or cancer, up to 10% in those with cardiovascular diseases.
      Sars-CoV-2 seems to be able to induce a functional exhaustion of specified T and NK
      lymphocyte subpopulations, breaking down antiviral immunity. One possible explanation is that
      the immune system of elderly people, might be exhausted by chronic stimulation associated
      with comorbidities and more susceptible to this Sars-CoV-2 effect. As a result, in these
      patients, the activation of the innate immune system might fail to produce an adequate
      adaptive response (i.e., virus-specific CD8+ T-cells). This results in persistent
      self-induced inflammation that eventually causes mortality.

      The investigators hypothesize that transfusing convalescent plasma (containing neutralizing
      antibodies) at an early phase of COVID-19 infection could prevent or switch off the
      persistent inflammatory response elicited by the virus.

      The objective of this study are:

        -  To demonstrate the superiority of COVID-19 convalescent plasma (CCP) plus standard
           therapy (ST) over ST alone

        -  To prevent progression of pneumonia in COVID-19 patients aged ≥65 with chronic
           comorbidities

        -  To decrease viral load

        -  To raise anti-SARS-CoV-2 antibody titer in recipients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of COVID-19 progression</measure>
    <time_frame>days 1 to 14.</time_frame>
    <description>Proportion of patients without progression in severity of pulmonary disease defined as worsening of 2 points in the ordinal scale of WHO within day 14</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Coronavirus Disease 2019 )COVID-19)</condition>
  <arm_group>
    <arm_group_label>Convalescent plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive COVID-19 Convalescent Plasma (CCP) in addition to standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive standard therapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Convalescent Plasma</intervention_name>
    <description>ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).</description>
    <arm_group_label>Convalescent plasma</arm_group_label>
    <other_name>CCP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 65

          -  pneumonia at CT scan

          -  PaO2/FiO2 ≥300 mmHg

          -  Presence of one or more comorbidities (consider the list provided in Appendix A)

          -  Signed informed consent

        Exclusion Criteria:

          -  Age &lt; 65

          -  PaO2/FiO2 &lt; 300 mmHg

          -  pending cardiopulmonary arrest

          -  refusal to blood product transfusions

          -  Severe IgA deficiency

          -  any life-threatening comorbidity or any other medical condition which, in the opinion
             of the investigator, makes the patient unsuitable for inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raffaele Landolfi, Prof.</last_name>
    <phone>06 30154435</phone>
    <phone_ext>+39</phone_ext>
    <email>raffaele.landolfi@unicatt.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luciana Teofili, Prof.</last_name>
    <phone>06 30154180</phone>
    <phone_ext>+39</phone_ext>
    <email>luciana.teofili@unicatt.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Landolfi, Prof.</last_name>
      <phone>0630154335</phone>
      <phone_ext>+39</phone_ext>
      <email>raffaele.landolfi@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Luciana Teofili</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonella Cingolani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maurizio Sanguinetti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale SS Annunziata</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacopo Vecchiet, Prof.</last_name>
      <phone>0871 357217</phone>
      <phone_ext>+39</phone_ext>
      <email>jacopo.vecchiet@unichi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Malattie Infettive Lazzaro Spallanzani</name>
      <address>
        <city>Rome</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Antinori, Prof.</last_name>
      <phone>06 55170348</phone>
      <phone_ext>+39</phone_ext>
      <email>andrea.antinori@inmi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 2, 2020</study_first_submitted>
  <study_first_submitted_qc>May 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

